CASI Pharmaceuticals (CASI) EBITDA (2020 - 2025)
CASI Pharmaceuticals (CASI) EBITDA from Dec 31, 2020 to Dec 31, 2025. The TTM CASI Pharmaceuticals (CASI) EBITDA is -$44M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
CASI Pharmaceuticals (CASI) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year | +14.33% |
| 3 Years | +10.09% |
| 5 Years | -3.44% |
| All Time | -3.44% |
Annual EBITDA change of CASI Pharmaceuticals (CASI)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$44M | +14.33% |
| 2024 | -$38M | +69.71% |
| 2023 | -$23M | -31.22% |
| 2022 | -$33M | -19.97% |
| 2021 | -$41M | -21.39% |
| 2020 | -$52M | N/A |
Comparison CASI Pharmaceuticals (CASI) five years EBITDA CAGR with competitors
CASI Pharmaceuticals (CASI) five years EBITDA CAGR is -3.44%.